Elan Corporation, plc (NYSE: ELN) announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer's disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology... (Source: Neurology / Neuroscience News From Medical News Today)